The tissue expression of TAGLN was significantly greater in patients with moderate (mean ± standard error of the mean; CKD stages 1 and 2, 8.50 ± 0.87%; CKD stage 3, 20.86%; p < 0.001) to advanced CKD (CKD stages 1 and 2; CKD stages 4 and 5, 19.85 ± 3.50%; p = 0.003) than in those with early CKD (Fig. 7a). Here, TAGLN is linked to chronic kidney disease.